Hirotsu Bio Science Inc.


USPTO Granted Patents = 11


Forward Citations = 1

Loading Chart...
Loading Chart...

21 inventors (with patents filed for the assignee):

goldMedal Takaaki Hirotsu (8 out of 8 patents)

silverMedal Hideto Sonoda (3 out of 3 patents)

bronzeMedal Masakazu Sugaya (2 out of 23 patents)

4.  Koichi Terada (2 out of 21 patents)

5.  Satoru Kaifuchi (2 out of 2 patents)

6.  Norihito Kuno (2 out of 7 patents)

7.  Taku Nakamura (2 out of 19 patents)

8.  Minoru Sakairi (2 out of 56 patents)

9.  Hirofumi Jono (1 out of 4 patents)

10.  Shogo Kobayashi (1 out of 8 patents)

11.  Takayuki Uozumi (1 out of 29 patents)

12.  Yuichiro Doki (1 out of 9 patents)

13.  Yuji Ueda (1 out of 8 patents)

14.  Takuma Yoshinaga (1 out of 1 patent)

15.  Hideshi Ishii (1 out of 4 patents)


11 patents:

Company Overview
Hirotsu Bio Science Inc. specializes in the development of advanced diagnostic solutions, focusing on early cancer detection and personalized medicine. The company leverages innovative technologies, including biomarker analysis and artificial intelligence, to enhance the accuracy and efficiency of its diagnostic platforms. Operating primarily in the healthcare sector, Hirotsu Bio Science aims to improve patient outcomes through cutting-edge research and development in the field of oncology diagnostics.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

11 Patents

#124 in

#490 in

#51,801 in the World

Forward Citations = 1

21 inventors:

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Hirotsu Bio Science Inc.. Retrieved from https://idiyas.com/company/hirotsu-bio-science

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…